Biotech Startup Renovacor Raises $11 Million

Want to share this story?

Philadelphia based startup Renovacor announced it raised new funding to promote new therapies for cardiovascular diseases.

The startup announced it has raised $11 million in Series A funding from lead investors BioAdvance, Novartis Venture Funds, and Broadview Ventures. Supporting investors in this round includes New Leaf Venture Partners and Innogest Capital.

The startup is a preclinical stage biotech company which develops improve therapies for genetically derived cardiovascular diseases. Renovacor is currently developing a gene therapy for a rare, familial version of dilated cardiomyopathy.

The company’s lead gene therapy product’s focus is to restore cardiac function in patients with symptomatic heart failure because of BAG3 gene mutation.